Protocol
LL-37 (5 mg Vial)
Complete dosage protocol and reconstitution guide for LL-37 (5 mg Vial).
Calculator preset
Run the vial math before tracking.
At ~1.67 mg/mL, 1 unit ~ 16.7 mcg ; 100 mcg ~ 6 units and 250 mcg ~ 15 units on a U-100 syringe.
01 · At a glance
Quickstart Highlights
LL‑37 (human cathelicidin) is a multifunctional host‑defense peptide with broad antimicrobial, immunomodulatory, and pro‑healing properties [1] [2] [3] . Clinical exploration has focused mainly on topical and intralesional use; a phase I melanoma study evaluated intratumoral injections with documented dermatologic changes and immune activation signals [6] [7] [8] . The subcutaneous framework below is a conservative, once‑daily microgram‑level layout to make syringe math clear; it is educational only and not a clinical dosing recommendation.
02 · Dosing & reconstitution
Dosing & Reconstitution Guide
A practical calculator-ready setup based on the imported protocol reference. Use these values as a math starting point, then verify every entry against your own vial, diluent, and professional guidance.
Standard / Gradual Approach (3.0 mL = ~1.67 mg/mL)
100–250 mcg once daily with gradual titration (keeps volumes ≤0.15 mL per injection; well within typical SC comfort limits) [10] .
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light.
- Avoid repeated freeze–thaw cycles. [11] [12]
03 · What you'll need
Supplies Needed
Keep this as a planning checklist. TNHL does not sell or verify supplies on this page, and no supplier quality claims are made here.
- 12 weeks ≈ 4 vials
- 16 weeks ≈ 5 vials
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
- 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Protocol Overview
- Goal: Illustrate microgram‑level SC measurement for a host‑defense peptide with documented antimicrobial, angiogenic, and wound‑healing biology [1] [2] .
- Schedule: Daily subcutaneous administration for 8–12 weeks (optional extension to 16 weeks); clinical LL‑37 studies to date are mainly topical or intralesional [4] [5] [7] . Dose Range (illustrative): 100–250 mcg once daily with gradual titration.
- Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for clear unit conversions.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid freeze–thaw cycles [11] [12] .
Dosing Protocol
- Suggested conservative titration for measurement clarity.
- Start: 100–150 mcg daily; increase by ~50 mcg every 1–2 weeks as tolerated.
- Target: 200–250 mcg daily by Weeks 5–8.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Choose a consistent time; rotate injection sites.
Storage Instructions
- Lyophilized: freeze at −20 °C (−4 °F) ; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) ; avoid repeated freeze–thaw cycles [11] [12] .
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid freeze–thaw cycles [11] [12] .
- Keep mixed and unmixed items clearly labeled so inventory and dose logs stay accurate.
04 · Good to know
Important Notes
- Practical considerations and safety context.
- Use a new sterile insulin syringe for each administration; dispose in a proper sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to limit local irritation and lipohypertrophy [13] .
- Inject slowly; wait a few seconds before withdrawing the needle to ensure full dose delivery.
- LL‑37 biology is context‑dependent; both pro‑healing and pro‑angiogenic or tumor‑promoting signals have been reported in specific models—interpret cautiously [8] [15] .
05 · How it works
How This Works
LL‑37 (human cathelicidin) is a multifunctional host‑defense peptide with broad antimicrobial, immunomodulatory, and pro‑healing properties [1] [2] [3] .
Clinical exploration has focused mainly on topical and intralesional use; a phase I melanoma study evaluated intratumoral injections with documented dermatologic changes and immune activation signals [6] [7] [8] .
The subcutaneous framework below is a conservative, once‑daily microgram‑level layout to make syringe math clear; it is educational only and not a clinical dosing recommendation.
The library page pairs that educational context with calculator-ready vial math, so users can understand the protocol structure and then track their own entered values in one place.
06 · Daily habits
Lifestyle Factors
- Keep meals, training, sleep, and recovery notes in the journal so trends are easier to review.
- Track body metrics only if they are relevant to the user's goal and approved data sources.
- Use consistent timing and logging habits so adherence data is meaningful.
07 · What to expect
Potential Benefits & Side Effects
- LL-37 observations should be recorded conservatively: expected research endpoints, tolerability notes, injection-site reactions when applicable, sleep, appetite, energy, mood, and any adverse or unusual response.
- This section is not a claim of therapeutic benefit.
08 · Technique
Injection Technique
- Wash hands with soap and water.
- Wipe the vial stopper and chosen site with alcohol, then let both dry.
- Confirm the vial concentration, calculator result, and intended draw amount before loading the syringe.
- Use the route and needle technique directed by a qualified professional or product instructions.
- For subcutaneous injections, rotate sites and inject slowly to limit leakage and irritation.
- Do not reuse needles or syringes.
- Dispose of sharps in a puncture-resistant container.
- Return stored items promptly to the correct temperature.
- Log dose, site, date, time, inventory change, and any observation.
09 · Evidence